Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease

Charles T. Quinn, Marie J. Stuart, Karen Kesler, Kenneth I. Ataga, Winfred C. Wang, Lori Styles, Kim Smith-Whitley, Ted Wun, Ashok Raj, Lewis L. Hsu, Suba Krishnan, Frans A. Kuypers, Yamaja Setty, Seungshin Rhee, Nigel S. Key, George R. Buchanan

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


Tapered oral dexamethasone for acute chest syndrome (ACS) in sickle cell anaemia was studied using a novel ACS assessment tool and investigational biomarkers. Twelve participants were randomized (mean age 17·3years) before early study termination. Dexamethasone decreased duration of hospitalization for ACS by 20·8h compared to placebo (P=0·024). Rebound pain occurred in both groups (3 dexamethasone versus 1 placebo). Overall, dexamethasone decreased the leucocyte activation biomarker, sL-selectin; however, participants with rebound pain had higher sL-selectin within 24h of treatment (dexamethasone or placebo). This ACS assessment tool was feasibly applied, and sL-selectin is a promising biomarker of ACS therapy.

Original languageEnglish (US)
Pages (from-to)263-267
Number of pages5
JournalBritish Journal of Haematology
Issue number2
StatePublished - Oct 2011


  • Acute chest syndrome
  • Biomarkers
  • Corticosteroid
  • L-selectin
  • Sickle cell disease

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease'. Together they form a unique fingerprint.

Cite this